Zoetis Inc. (NYSE:ZTS) Shares Purchased by Isthmus Partners LLC

Isthmus Partners LLC raised its holdings in Zoetis Inc. (NYSE:ZTS) by 0.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 68,821 shares of the company’s stock after acquiring an additional 173 shares during the period. Isthmus Partners LLC’s holdings in Zoetis were worth $11,213,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. State Street Corp increased its stake in Zoetis by 0.5% in the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after purchasing an additional 95,856 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Zoetis by 1.8% during the 3rd quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after acquiring an additional 185,364 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Zoetis by 8.5% during the 4th quarter. Bank of New York Mellon Corp now owns 5,561,910 shares of the company’s stock valued at $906,202,000 after acquiring an additional 433,429 shares during the last quarter. Mizuho Securities USA LLC lifted its holdings in shares of Zoetis by 13,726.9% during the 3rd quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after acquiring an additional 4,829,815 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock valued at $761,221,000 after acquiring an additional 194,542 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on ZTS. Piper Sandler raised their price objective on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday. Stifel Nicolaus lowered their price objective on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 target price on the stock. Finally, Barclays upped their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One analyst has rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $215.90.

Zoetis Price Performance

ZTS opened at $170.34 on Monday. The firm has a market cap of $76.28 billion, a price-to-earnings ratio of 31.14, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company’s 50-day moving average price is $166.72 and its 200 day moving average price is $176.74. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $200.33.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, topping the consensus estimate of $1.37 by $0.03. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. The firm had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is currently 36.56%.

Insider Buying and Selling at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at approximately $2,757,196.26. This trade represents a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is owned by company insiders.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.